Towseef Amin Rafeeqi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Towseef Amin Rafeeqi has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Alokananda Chakraborty
BCMB Laboratory, National Research Institute of Unani Medicine for Skin Disorders, ESI x Road, Hyderabad, Telangana, India
2 shared publications Arjumand Shah
2 shared publications- Gulam Mohammed Husain
National Research Institute of Unani Medicine for Skin Disorders
2 shared publications - Naquibul Islam
Professor, Department of Mo‘ālajāt, Regional Research Institute of Unani Medicine,S rinagar, J&K, India
2 shared publications Riyaz Ahmed Pandith
2 shared publicationsSeema Akbar
2 shared publications
Latest Publications
- Open Access
- 29 June 2026
- Published by Elsevier in SSRN Electronic Journal
In Vitro Coagulant and Haemostatic Activities of Potamogeton natans L. (Jar-ul-Nahr): An Aquatic Plant from Dal Lake, Kashmir
Ethnopharmacological relevance: Herbal medicines are traditionally used to manage bleeding and thrombotic disorders, offering potential as safer alternatives to conventional therapies. In Unani medicine, Potamogeton natans L. (Jar-ul-Nahr) is regarded as a coagulant, though scientific validation is limited. Aim of the Study: The objective of this study was to examine the procoagulant and thrombolytic properties of various extracts derived from Potamogeton natans L. Material and Methods: Plant material was collected from Dal Lake, Kashmir, India. Petroleum ether, ethyl acetate, methanolic, and hydroalcoholic extracts of Potamogeton natans L. were prepared. Coagulation assays like prothrombin time (PT), Activated Partial Thromboplastin Time (aPTT) test and Plasma recalcification test (PRT) were performed at extract concentrations ranging from 0.25 to 4 mg/mL. Thrombolytic activity was assessed by a clot lysis assay, with 10% DMSO as the negative control and 100 µl Streptokinase as the positive control. Results: Our results show that at lower concentrations, petroleum ether had the strongest thrombolytic and procoagulant action, while methanol and hydroalcoholic extracts had more diverse effects. Ethyl Acetate exhibited both pro-coagulant and modulatory activity depending on dose. In the clot lysis assay, the negative control produced 16.9% lysis, whereas Streptokinase achieved 52.36%. Combinations of Streptokinase with extracts resulted in intermediate clot lysis (31.9% - 41%), with Petroleum Ether–Streptokinase showing the highest activity (41%). When tested alone, extracts produced lower lysis (16.5%–22%), with Petroleum Ether again performing best (22%). All experimental groups showed statistically significant differences compared with the control. Conclusion This research offers scientific proof that supports the conventional use of Potamogeton natans L. as a natural haemostatic agent. The extracts of Petroleum Ether and Ethyl Acetate demonstrate dual pharmacological capabilities by promoting coagulation and improving clot lysis.
- 29 June 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessIn Vitro Coagulant and Haemostatic Activities of Potamogeton natans L. (Jar-ul-Nahr): An Aquatic Plant from Dal Lake, Kashmir
Ethnopharmacological relevance: Herbal medicines are traditionally used to manage bleeding and thrombotic disorders, offering potential as safer alternatives to conventional therapies. In Unani medicine, Potamogeton natans L. (Jar-ul-Nahr) is regarded as a coagulant, though scientific validation is limited. Aim of the Study: The objective of this study was to examine the procoagulant and thrombolytic properties of various extracts derived from Potamogeton natans L. Material and Methods: Plant material was collected from Dal Lake, Kashmir, India. Petroleum ether, ethyl acetate, methanolic, and hydroalcoholic extracts of Potamogeton natans L. were prepared. Coagulation assays like prothrombin time (PT), Activated Partial Thromboplastin Time (aPTT) test and Plasma recalcification test (PRT) were performed at extract concentrations ranging from 0.25 to 4 mg/mL. Thrombolytic activity was assessed by a clot lysis assay, with 10% DMSO as the negative control and 100 µl Streptokinase as the positive control. Results: Our results show that at lower concentrations, petroleum ether had the strongest thrombolytic and procoagulant action, while methanol and hydroalcoholic extracts had more diverse effects. Ethyl Acetate exhibited both pro-coagulant and modulatory activity depending on dose. In the clot lysis assay, the negative control produced 16.9% lysis, whereas Streptokinase achieved 52.36%. Combinations of Streptokinase with extracts resulted in intermediate clot lysis (31.9% - 41%), with Petroleum Ether–Streptokinase showing the highest activity (41%). When tested alone, extracts produced lower lysis (16.5%–22%), with Petroleum Ether again performing best (22%). All experimental groups showed statistically significant differences compared with the control. Conclusion This research offers scientific proof that supports the conventional use of Potamogeton natans L. as a natural haemostatic agent. The extracts of Petroleum Ether and Ethyl Acetate demonstrate dual pharmacological capabilities by promoting coagulation and improving clot lysis.
- Open Access
- 17 March 2026
- Published by Elsevier in SSRN Electronic Journal
Evaluation of therapeutic efficacy of Habb-e-Asgand a Unani Formulation in the management of Waja‘al-Mafāṣil (Rheumatoid arthritis) and its effect on serum biomarkers: a randomized standard controlled clinical trial
Background: Unani System of medicine provides an alternative source to relieve the symptoms of Rheumatoid Arthritis, to slow the progression of disease, and to tackle the disadvantages associated with conventional drugs. Habb-e-Asgand is an important Unani pharmacopeial formulation which is commonly prescribed for Rheumatoid Arthritis. Hence, current study is designed to investigate its efficacy and safety in the management of Waja‘ al-Mafāṣil (Rheumatoid Arthritis).Methods: This parallel group, randomized, single blind clinical trial compared unani formulation Habb-e-Asgand 2pills (each of 650mg) at bed time orally, with Sulfasalazine 500 mg tablets twice a day orally as control. The total number of patients completing the trial was 20 in each group and treatment was given for 45 days. For evaluating subjective parameters, patients were asked to follow up every 15 days during the trial and objective parameters were assessed on the 0th and 46th days of the trial.Results: There was statistically significant difference between Test and Control treatment with respect to subjective parameters, joint pain (p-value˂0.0001*), morning stiffness (pvalue˂0.0001*), joints swelling (p-value˂0.0001*), joints tenderness (p-value˂0.0001*), restricted movement of the joints (p-value˂0.002*) which means that the treatments in the test group were more effective in resolving them. The objective parameter such as HAQ-DI, DAS-28, RA factor and soft tissue swelling on x-ray show statistically significant reduction in test group in comparison to the control group with p-value.Conclusion: These finding suggested that Habb-e-Asgand is safely and effectively used in the management of Waja‘ al-Mafāṣil (Rheumatoid Arthritis).Trial registration: CTRI no.- CTRI/2022/01/039602.
- 17 March 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessEvaluation of therapeutic efficacy of Habb-e-Asgand a Unani Formulation in the management of Waja‘al-Mafāṣil (Rheumatoid arthritis) and its effect on serum biomarkers: a randomized standard controlled clinical trial
Background: Unani System of medicine provides an alternative source to relieve the symptoms of Rheumatoid Arthritis, to slow the progression of disease, and to tackle the disadvantages associated with conventional drugs. Habb-e-Asgand is an important Unani pharmacopeial formulation which is commonly prescribed for Rheumatoid Arthritis. Hence, current study is designed to investigate its efficacy and safety in the management of Waja‘ al-Mafāṣil (Rheumatoid Arthritis).Methods: This parallel group, randomized, single blind clinical trial compared unani formulation Habb-e-Asgand 2pills (each of 650mg) at bed time orally, with Sulfasalazine 500 mg tablets twice a day orally as control. The total number of patients completing the trial was 20 in each group and treatment was given for 45 days. For evaluating subjective parameters, patients were asked to follow up every 15 days during the trial and objective parameters were assessed on the 0th and 46th days of the trial.Results: There was statistically significant difference between Test and Control treatment with respect to subjective parameters, joint pain (p-value˂0.0001*), morning stiffness (pvalue˂0.0001*), joints swelling (p-value˂0.0001*), joints tenderness (p-value˂0.0001*), restricted movement of the joints (p-value˂0.002*) which means that the treatments in the test group were more effective in resolving them. The objective parameter such as HAQ-DI, DAS-28, RA factor and soft tissue swelling on x-ray show statistically significant reduction in test group in comparison to the control group with p-value.Conclusion: These finding suggested that Habb-e-Asgand is safely and effectively used in the management of Waja‘ al-Mafāṣil (Rheumatoid Arthritis).Trial registration: CTRI no.- CTRI/2022/01/039602.
- Open Access
- 15 March 2024
- Published by Society of Pharmaceutical Tecnocrats in Journal of Drug Delivery and Therapeutics
- Vol. 14 (3) , 8-21
Clinical study to Evaluate Safety and Efficacy of Boozidaan (Pyrethrum indicum) in the management of Niqris Muzmin (Chronic Gout)
Objectives: The objectives of this study were to observe the Efficacy of unani pharmacopoeial formulation Boozidan (Pyrethrum indicum) for the management of Niqris Muzmin (Chronic gout) and to observe any concomitant and adverse effects of formulation. Methods: This single blind, randomized and standard control clinical study was conducted between April 2021 to October 2021 for a period of 28 days. 60 patients diagnosed with chronic gout were divided into two groups, 30 Test group and 30 Control group. The test group was administered with 5g boozidaan in powder form once daily with water and the patients of control group were given tablet febuxostat 80mg once daily. Patients were followed up and improvements in subjective parameters were assessed weekly at 7th, 14th, 21st, and 29th day. Objective parameters were assessed at the baseline and at 29th day. The data obtained was subjected to statistical analysis. Results: Both the test and control drug were effective in reducing Serum uric acid level, ESR and CRP levels. A significant improvement in subjective and objective parameters was observed in both test and control groups and no adverse effects were observed during and after the study. However, the test drug had superior efficacy in reducing the objective parameters and it was statistically significant (p-value<0.0001). Conclusion: Both Boozidaan and Febuxostat were safe and significantly effective in resolving the symptoms and signs of gouty arthritis and both have significant effect on reducing serum uric acid level. Keywords: Boozidaan, Chronic gout, Niqris, Febuxostat, serum uric acid, unani medicine
- 15 March 2024
- Published by Society of Pharmaceutical Tecnocrats in Journal of Drug Delivery and Therapeutics
- Vol. 14 (3) , 8-21
Open AccessClinical study to Evaluate Safety and Efficacy of Boozidaan (Pyrethrum indicum) in the management of Niqris Muzmin (Chronic Gout)
Objectives: The objectives of this study were to observe the Efficacy of unani pharmacopoeial formulation Boozidan (Pyrethrum indicum) for the management of Niqris Muzmin (Chronic gout) and to observe any concomitant and adverse effects of formulation. Methods: This single blind, randomized and standard control clinical study was conducted between April 2021 to October 2021 for a period of 28 days. 60 patients diagnosed with chronic gout were divided into two groups, 30 Test group and 30 Control group. The test group was administered with 5g boozidaan in powder form once daily with water and the patients of control group were given tablet febuxostat 80mg once daily. Patients were followed up and improvements in subjective parameters were assessed weekly at 7th, 14th, 21st, and 29th day. Objective parameters were assessed at the baseline and at 29th day. The data obtained was subjected to statistical analysis. Results: Both the test and control drug were effective in reducing Serum uric acid level, ESR and CRP levels. A significant improvement in subjective and objective parameters was observed in both test and control groups and no adverse effects were observed during and after the study. However, the test drug had superior efficacy in reducing the objective parameters and it was statistically significant (p-value<0.0001). Conclusion: Both Boozidaan and Febuxostat were safe and significantly effective in resolving the symptoms and signs of gouty arthritis and both have significant effect on reducing serum uric acid level. Keywords: Boozidaan, Chronic gout, Niqris, Febuxostat, serum uric acid, unani medicine
- 23 April 2022
- Published by A and V Publications in Research Journal of Pharmacy and Technology
- Vol. 15 (4) , 1560-1566
Effect of Anti-inflammatory Activity of Aqueous, Hydro-ethanol and Methanol extracts of two Unani formulations
- 23 April 2022
- Published by A and V Publications in Research Journal of Pharmacy and Technology
- Vol. 15 (4) , 1560-1566
Effect of Anti-inflammatory Activity of Aqueous, Hydro-ethanol and Methanol extracts of two Unani formulations
- Open Access
- 1 January 2022
- Published by Wolters Kluwer Health in Hippocratic Journal of Unani Medicine
- Vol. 17 (1) , 20-24
Long-term Safety of Coded Unani Formulation and PUVASOL in Patients with Vitiligo - A Randomized Comparative Controlled Clinical Trial
Background: Vitiligo, a skin disorder is viewed as a multifactorial process characterized by the acquired loss of constitutional pigmentation manifesting as white macules and patches. The Unani system of medicine offers many formulations including the ones designed by the Central Council for Research in Unani Medicine for the successful treatment of vitiligo. Aims and Objectives: Herein, we evaluated the comparative long-term safety (9 months) of test Unani formulation (UNIM 001 and UNIM 003) with controlled allopathic therapy (PUVASOL: Psoralen and UVA obtained by solar light) in terms of blood parameters. Materials and Methods: In this clinical study, 39 vitiligo patients in the test group and 33 vitiligo patients in the control group were assessed for blood parameters viz., aspartate aminotransferase, alanine aminotransferase, bilirubin, urea, creatinine, hemoglobin, red blood cells, white blood cell, and Platelet before, during, and after the treatment period. Results: All the blood parameters were in the normal biological reference range in the test and control group at the baseline, during the treatment, and at the end of the study. These results indicate that at a given dose of the UNIM-001 and UNIM 004, there is no effect on the liver, kidney, and other hematological blood parameters in the patients with vitiligo and are comparable with PUVASOL therapy. Conclusion: A combination of Unani formulation i.e., UNIM 001 as oral and UNIM 003 as topical application may be considered an effective and safe treatment alternative to patients with vitiligo.
- 1 January 2022
- Published by Wolters Kluwer Health in Hippocratic Journal of Unani Medicine
- Vol. 17 (1) , 20-24
Open AccessLong-term Safety of Coded Unani Formulation and PUVASOL in Patients with Vitiligo - A Randomized Comparative Controlled Clinical Trial
Background: Vitiligo, a skin disorder is viewed as a multifactorial process characterized by the acquired loss of constitutional pigmentation manifesting as white macules and patches. The Unani system of medicine offers many formulations including the ones designed by the Central Council for Research in Unani Medicine for the successful treatment of vitiligo. Aims and Objectives: Herein, we evaluated the comparative long-term safety (9 months) of test Unani formulation (UNIM 001 and UNIM 003) with controlled allopathic therapy (PUVASOL: Psoralen and UVA obtained by solar light) in terms of blood parameters. Materials and Methods: In this clinical study, 39 vitiligo patients in the test group and 33 vitiligo patients in the control group were assessed for blood parameters viz., aspartate aminotransferase, alanine aminotransferase, bilirubin, urea, creatinine, hemoglobin, red blood cells, white blood cell, and Platelet before, during, and after the treatment period. Results: All the blood parameters were in the normal biological reference range in the test and control group at the baseline, during the treatment, and at the end of the study. These results indicate that at a given dose of the UNIM-001 and UNIM 004, there is no effect on the liver, kidney, and other hematological blood parameters in the patients with vitiligo and are comparable with PUVASOL therapy. Conclusion: A combination of Unani formulation i.e., UNIM 001 as oral and UNIM 003 as topical application may be considered an effective and safe treatment alternative to patients with vitiligo.
- Open Access
- 30 December 2021
- Published by BioMed Research Publishers in Journal of Ayurvedic and Herbal Medicine
- Vol. 7 (4) , 229-231
An effective treatment of ostraceous psoriasis by Unani medicine- A case report from Kashmir North India
- 30 December 2021
- Published by BioMed Research Publishers in Journal of Ayurvedic and Herbal Medicine
- Vol. 7 (4) , 229-231
Open AccessAn effective treatment of ostraceous psoriasis by Unani medicine- A case report from Kashmir North India
- 21 December 2019
- Published by Walter de Gruyter GmbH in Journal of Complementary and Integrative Medicine
- Vol. 17 (3)
Oxidative stress in Vitiligo patients and administration of Munzij and Mushil therapy, a poly herbal Unani formulation – hospital-based study
Background: Vitiligo, a skin disorder is viewed as a multifactorial process with major role of reactive oxygen species in concert to destroy or incapacitate melanocytes. In Unani system of medicine the treatment of Bars (Vitiligo) starts with removal of harmful materials from the body with Munzij and Mushil (MM), a poly herbal Unani formulation. Methods: Herein, oxidative stress related parameters as MDA, SOD, GPx and CAT have been estimated in the 21 clinically diagnosed Vitiligo in-patients and subsequently these parameters were evaluated during and after administration of MM therapy and compared with 21 healthy subjects. Results: There was significant difference in the parameters viz., SOD (p<0.001) and CAT (p<0.005) activity at the baseline with no statistical significant difference in MDA and GPx activity among Vitiligo subjects and controls. After MM therapy there was no statistical significant difference among the values of these parameters in Vitiligo subjects. Conclusions: The results suggest that there is imbalance in the oxidant-antioxidant status of Vitiligo subjects and the MM therapy is not found to significantly change the levels of oxidative stress related parameters.
- 21 December 2019
- Published by Walter de Gruyter GmbH in Journal of Complementary and Integrative Medicine
- Vol. 17 (3)
Oxidative stress in Vitiligo patients and administration of Munzij and Mushil therapy, a poly herbal Unani formulation – hospital-based study
Background: Vitiligo, a skin disorder is viewed as a multifactorial process with major role of reactive oxygen species in concert to destroy or incapacitate melanocytes. In Unani system of medicine the treatment of Bars (Vitiligo) starts with removal of harmful materials from the body with Munzij and Mushil (MM), a poly herbal Unani formulation. Methods: Herein, oxidative stress related parameters as MDA, SOD, GPx and CAT have been estimated in the 21 clinically diagnosed Vitiligo in-patients and subsequently these parameters were evaluated during and after administration of MM therapy and compared with 21 healthy subjects. Results: There was significant difference in the parameters viz., SOD (p<0.001) and CAT (p<0.005) activity at the baseline with no statistical significant difference in MDA and GPx activity among Vitiligo subjects and controls. After MM therapy there was no statistical significant difference among the values of these parameters in Vitiligo subjects. Conclusions: The results suggest that there is imbalance in the oxidant-antioxidant status of Vitiligo subjects and the MM therapy is not found to significantly change the levels of oxidative stress related parameters.